Parabilis Medicines is gearing up for an IPO that could eventually bring in as much as $476 million to fund the phase 3 development of its desmoid tumor prospect. https://t.co/THXbl1svOW
Innovent Biologics has reported a phase 3 victory for IBI343, boosting the prospects of an antibody-drug conjugate that Takeda bet big on last year https://t.co/sDyxWf0aCq
Praxis Precision Medicines’ epilepsy pipeline has suffered a setback after a next-gen NaV blocker failed to sufficiently reduce seizures in a phase 2/3 study https://t.co/yxaJUX6eBu
To Roche, a phase 3 flop in first-line breast cancer does not erase the megablockbuster potential of its oral SERD drug giredestrant even as competition mounts https://t.co/ZJkQKCYEsM #ASCO26
Fulcrum Therapeutics has scrapped its sole clinical-stage program after the FDA took a hard line on the modality following the recent withdrawal of Ipsen’s Tazverik from the U.S. market. https://t.co/MrF8yUC5A7
With Innovent Biologics garnering buzz in the dealmaking space, Takeda is adding more credence to its own multi-billion-biobucks collab with the Chinese company that granted access to a first-in-class bispecific with “tremendous potential.” https://t.co/ohDtnHS58R #ASCO26
GSK shared early data suggesting its KIT inhibitor from IDRx could overtake Gleevec as the standard of care for gastrointestinal stromal tumors. https://t.co/B0S8hvzKe8 #ASCO26
Kelonia Therapeutics has shared the largest slice of data yet for its in vivo CAR-T, helping to justify the $3.2 billion price tag that Eli Lilly recently paid to buy the Boston biotech. https://t.co/6y09ypAQaP